Esperion ETC 1002-043 Bempedoic Acid

Investigator: Mahendra Jain, MD

Study Coordinator: Bela Jain

Status: Enrolling

ClinicalTrials.gov Number: NCT02993406

Phone: 281.485.3434

Protocol Number: Pro00018397

Description

To evaluate whether long-term treatment with bempedoic acid 180 mg/day versus placebo reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease (CVD) who are statin intolerant. This will be assessed with a composite primary efficacy endpoint that includes time to first occurrence of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for unstable angina, or coronary revascularization
More to Explore